While beyond the scope of the currently study, it would be plausible to orally administer digested and undigested recombinant C. jejuni-specific human IgA in the context of a mouse model of C. jejuni infection and investigate the differential impact on infection outcome and gut microbiota diversity. The gene discussed is CD79A; the disease is infection.